Kornimate/medical-research-clean huggingface dataset:
role of prophylactic antibiotics in preventing pelvic infection after surgical evacuation

Conditions: Antibiotics Causing Adverse Effects in Therapeutic Use

Summary: to determine the role of antibiotic prophylaxis in the surgical management of miscarriage.

patients will be randomized to receive either prophylactic antibiotic \[a single dose of oral doxycycline (200 mg) and metronidazole (500 mg)\] or placebo using identical sealed envelopes.included cases are those with early miscarriage (within the first trimester 12 6/7 weeks of gestation) , missed or incomplete miscarriage, undergoing surgical management will be included in the study. technique: the investigators will prepare 138 identical envelops, half of them filled with a label group(1) who are the group to receive the antibiotic prophylaxis with all instruction details, while the other half filled with a label identifying ( group 2) who are the placebo group. all envelops will be prepared by the investigator and sealed before starting enrollment. after enrollment, each participant will be allowed to choose one envelop to determine to which group the patient will be assigned to.

Eligibility criteria:
inclusion criteria: * maternal age :18-35 years * gestational age: up to 12 6/7 weeks of gestation (confirmed by a reliable date for the last menstrual period or /and 1st trimester ultrasound scan). * singleton miscarriage * type of miscarriage: incomplete or missed miscarriage * surgical evacuation will be done within 2 weeks of diagnosis of miscarriage . exclusion criteria: * maternal age: younger than 18 years * induced miscarriage of pregnancy * septic miscarriage * evidence of infection * morbid obesity (bmi≥40kg/m2) * allergy to prophylactic antibiotics (i.e., doxycycline or metronidazole) * antibiotics use within 7 days before randomization
oral losartan in prevention of post-ercp paancreatitis

Conditions: Post-ERCP Acute Pancreatitis

Summary: oral losartan given in the dose of 50 mg one hour before ercp was studied in the prevention of post ercp pancreatitis in 50 patients indicated for ercp in comparison with another 50 patients underwent ercp without receiving oral losartan.


Eligibility criteria:
inclusion criteria: * any adult patient indicated for ercp * patients with obstructive jaundice. * patients with dilated intra-hepatic or extra-hepatic bile ducts due to malignant or benign lesions. exclusion criteria: * patients refusing to undergo the procedure or signing the informed consent * patients with clinically evident acute pancreatitis before the procedure * patients with previous endoscopic or surgical sphincterotomy * patients with current use of losartan * patients who are allergic or hypersensitive to losartan or hydro soluble contrast solutions * patients receiving nsaids within a week prior to assessment * patients with severe co-morbid conditions as cardiovascular disease, renal failure or decompensated liver cirrhosis.
pilot text message for influenza vaccination

Conditions: Influenza

Summary: influenza is an important and potentially preventable cause of morbidity and mortality, yet only 46% of u.s. adults were vaccinated by the end of the 2011-12 influenza season despite influenza vaccination being widely recommended, effective, and safe. influenza vaccination rates are even lower in racial/ethnic minority groups. in order to address the problem of low influenza vaccination rates in minority adults, we plan to build on the well-accepted practice of immunization recall-reminders and the emerging practice of using text message to pilot the feasibility of using text messaging to improve influenza vaccination coverage rates in a low health literacy, largely minority, publicly insured adult population.


Eligibility criteria:
inclusion criteria: * \> or = 18 years of age, * at least one visit to the aim clinic during the previous year * a cell phone number in the registration system * fluent in english or spanish. exclusion criteria exclusion criteria: * receipt of influenza vaccination during the 2012-2013 influenza season prior to randomization.

Keywords: influenza vaccination
study of carboplatin/paclitaxel in combination with abt-869 in subjects with advanced or metastatic non-small cell lung cancer (nsclc)

Conditions: Advanced or Metastatic Non-Small Cell Lung Cancer

Summary: this study is designed to determine the clinical efficacy and toxicity of abt-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic nsclc.


Eligibility criteria:
inclusion criteria: * subject must be at least 18 years of age. * subject must have cytologically or histologically confirmed non-squamous nsclc * subject must have recurrent or advanced (stage iiib with pleural or pericardial effusion) or metastatic (stage iv) disease that is not amenable to surgical resection or radiation with curative intent. * subject has measurable disease, defined as at least 1 unidimensional measurable lesion on a computed tomography (ct) scan as defined by recist (for subjects in the randomized portion only). * subject has an ecog performance score of 0-1. * willing to take adequate measures to prevent pregnancy. exclusion criteria: * the subject has nsclc with a predominant squamous cell histology * subject has hypersensitivity to paclitaxel. * subject has received any anti-cancer therapy for treatment of nsclc. * subject has received radiation therapy within 21 days of study day 1. * subject has had major surgery within 21 days. * subject has untreated brain or meningeal metastases. * subject is receiving therapeutic anticoagulation therapy. * subject has a central thoracic tumor lesion as defined by location within the hilar structures. * subject has proteinuria ctc grade \> 1 at baseline. * subject has a history of, or currently exhibits clinically significant cancer related events of bleeding. * the subject currently exhibits symptomatic or persistent, uncontrolled hypertension defined as diastolic blood pressure (bp) \> 90 mm hg or systolic bp \> 140 mm hg. * the subject has a history of myocardial infarction, stroke or transient ischemic attack (tia) within 6 months of study day 1. * the subject has a documented left ventricular (lv) ejection fraction \< 50%. * the subject has known autoimmune disease with renal involvement (i.e., lupus). * the subject is receiving combination anti-retroviral therapy for hiv. * the subject has clinically significant uncontrolled condition(s). * the subject has a history of another active cancer within the past 5 years. * the subject has active ulcerative colitis, crohn's disease, celiac disease or any other conditions that interfere with absorption. * the subject has a medical condition, which in the opinion of the study investigator places them at an unacceptably high risk for toxicities. * the subject is pregnant or breast feeding.
advantig-202: anti-pd-1 monoclonal antibody tislelizumab (bgb-a317) combined with or without anti-tigit monoclonal antibody ociperlimab (bgb-a1217) in participants with previously treated recurrent or metastatic cervical cancer

Conditions: Cervical Cancer

Summary: this study tested how well and how safely the drug tislelizumab, given either alone or with another drug called ociperlimab (bgb-a1217), worked in people with cervical cancer that had come back or spread after previous treatments. the study included two groups and took place at multiple medical centers.


Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix. 2. progression on or after one or more lines of chemotherapy for management of recurrent or metastatic disease and is not amenable to curative treatment (eg, systemic chemotherapy, surgery, or radiotherapy). 3. measurable disease as assessed by recist v1.1. note: a lesion in an area subjected to prior loco-regional therapy, including previous radiotherapy, is not considered measurable unless there has been demonstrated progression in the lesion since the therapy as defined by recist v1.1. 4. participants must submit qualified archival tumor tissue (formalin-fixed paraffin-embedded block containing tumor \[preferred\] or approximately 15 \[at least 6\] unstained slides) with an associated pathology report, or agree to a tumor biopsy for determination of programmed death-ligand 1 (pd-l1) expression and other biomarker analyses (fresh tumor biopsies are strongly recommended at baseline in participants with readily accessible tumor lesions and who consent to the biopsies). 5. participant must have adequate organ function as indicated by the screening laboratory values obtained within 7 days before the first study treatment. exclusion criteria: 1. prior therapy with an anti-pd-1, anti-pd-l1, anti-pd-l2, tigit or any other antibody or drug specifically targeting t-cell costimulation or checkpoint pathways. 2. any active malignancy ≤ 2 years before first dose of study drug except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of breast). 3. uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within 2 weeks of intervention). 4. any major surgical procedure ≤ 28 days before first dose of study drug. participants must have recovered adequately from the toxicity and/or complications from the intervention before the first dose of study drug. 5. has received any chemotherapy, immunotherapy (eg, interleukin, interferon, thymosin, etc.) or any investigational therapies within 14 days or 5 half-lives (whichever is longer) before the first dose of study drug or has received palliative radiation treatment or other local regional therapies within 14 days before the first dose of study drug. note: other protocol defined inclusion/exclusion criteria may apply
chidamide for patients with recurrent and metastatic epstein-barr virus (ebv)-associated solid tumors

Conditions: Experimental Tumor

Summary: study of chidamide as a single-agent treatment for patients with recurrent and metastatic epstein-barr virus (ebv)-associated solid tumors

chidamide，a novel histone deacetylase inhibitor has been approved for the treatment of relapsed or refractory peripheral t-cell lymphoma in china. the aim of this study was to observe the efficacy and safety of chidamide as a single-agent treatment in patients with recurrent and metastatic epstein-barr virus (ebv)-associated solid tumors.

Eligibility criteria:
inclusion criteria: 1. diagnosed as recurrent and metastatic epstein-barr virus (ebv)-associated solid tumors, including nasopharyngeal carcinoma and other solid tumors (lymphoma excluded). patients must have failed at least one systemic treatment and been refractory to platinum-containing regimens; 2. at least one measurable lesion according to criteria recist v1.1; 3. age 18-70 years, male or female; 4. ecog performance status 0-2; 5. life expectancy no less than 3 months; 6. adequate hepatic, renal and bone marrow function; 7. history of brain metastasis is eligible, but maintenance of hormone is not required; 8. contraception during and 4 weeks after the study for patients at child bearing age; 9. patients have signed the informed consent form. exclusion criteria: 1. women during pregnancy or lactation, or fertile women unwilling to take contraceptive measures; 2. qtc elongation with clinical significance ( male˃ 450ms, female˃ 470ms), ventricular tachycardia, atrial fibrillation, cardiac conducting blockage, myocardial infarction within 1 year, congestive heart failure, symptomatic coronary heart disease that requires treatment; 3. pericardial effusion ≥10mm sum of echo-free spaces by echocardiography; 4. patients have undergone organ transplantation; 5. patients received symptomatic treatment for bone marrow toxicity within 7 days prior to enrollment; 6. patients with active hemorrhage; 7. patients with or with history of thrombosis, embolism, cerebral hemorrhage, or cerebral infarction; 8. patients with active hbv or hcv infection; 9. continuous fever within 14 days prior to enrollment; 10. had major organ surgery within 6 weeks prior to enrollment; 11. impaired liver function ( total bilirubin ˃ 1.5 times of normal maximum, alt/ast˃ 2.5 times of normal maximum, for patients with infiltrative liver disease alt/ast ˃ 5 times of normal maximum), impaired renal function (serum creatinin˃ 1.5 times of normal maximum); 12. patients with mental disorders or those do not have the ability to consent; 13. patients with drug abuse, long term alcoholism that may impact the results of the trial; 14. patients who received treatment of hdac inhibitors; 15. non-appropriate patients for the trial according to the judgment of the investigators.
management of oab in female patients .

Conditions: Overactive Bladder

Summary: the objective of this study is to compare the effectiveness of mirabegron, solifenacin, tadalafil (5mg), and their combination in relieving symptoms of overactive bladder (oab) in a double-blinded prospective randomized placebo-controlled trial.


Eligibility criteria:
inclusion criteria: * women from 18 to 65 years of age with luts due to oab exclusion criteria: * severe cardiovascular disorders. \\ * severe neurogenic dysfunction. * drug administration which interfere with bladder function . * abnormal bleeding profile. * a verified urinary tract infection as determined by urinalysis and/or urine culture during screening
early transcranial doppler goal directed therapy after cardiac arrest: a pilot study

Conditions: Cardiac Arrest; Cerebral Lesion; Ischemic Encephalopathy; Ischemic Reperfusion Injury

Summary: hypoxic-ischaemic brain injury (hibi) is the main cause of death in patients who are comatose after resuscitation from cardiac arrest. current guidelines recommend to target a mean arterial pressure (map) above 65 mmhg to achieve an adequate organ perfusion. moreover, after cardiac arrest, cerebral autoregulation is dysregulated and cerebral blood flow (cbf) depends on the map. a higher blood pressure target could improve cerebral perfusion and hibi. transcranial doppler (tcd) is a non-invasive method to study cbf and its variations induced by map. the aim of this study is to test the feasibility of an early-goal directed hemodynamic management with tcd during the first 12 hours after return of spontaneous circulation (rosc).


Eligibility criteria:
inclusion criteria: * patients admitted in the intensive care unit (icu) under mechanical ventilation with a glasgow coma scale ≤ 8/15 after in- or out-of-hospital cardiac arrest * mean arterial pressure between 65 and 85 mmhg with or without vasopressor support exclusion criteria: * age \< 18 years old * no flow (time between cardiac arrest and the beginning of cardiac massage) \> 15 minutes or unknown * low flow ((time between cardiac arrest and rosc: return of spontaneous circulation)\> 60 minutes * time between rosc and inclusion \> 12 hours * transcranial doppler unavailable * cardiac arrythmia * patient under extracorporeal life support before inclusion or at risk of being referred for assistance due to cardiogenic shock with high dose of vasopressors before inclusion (map \ 1 µg/kg/min or dobutamine \> 10 µg/kg/min) * severe cardiac dysfunction defined by left ventricular ejection fraction \ 10µg/kg/min * patient under extracorporeal membrane oxygenation (ecmo) for acute respiratory distress syndrome (ards) before inclusion * cardiac arrest secondary to brain injury such as stroke, subarachnoid hemorrhage or traumatic brain injury * hemorrhagic shock * any acute pathology that requires strict blood pressure control (aortic dissection, stroke, cardiogenic pulmonary edema with high blood pressure) * decision of withdrawing or withholding life sustaining treatment before inclusion or considered during the first 12 hours of icu management * patient with a modified rankin scale (mrs) 4 or 5 prior to resuscitation * pregnancy or lactation * patients already enrolled in another clinical study on cardiac arrest * patients with judicial protection * no social security coverage

Keywords: cardiac arrest cerebral blood flow cerebral autoregulation transcranial doppler
effect of 3d printing functional hand splints for patients with stroke

Conditions: Stroke

Summary: the study is to evaluate the effect of 3d printing functional splints on hand function for patients with stroke.twenty stroke patients with moderate motor deficits were recruited and randomized into experimental (3d printing splint) or control (functional splint) groups for 8 weeks of treatment.the performance was assessed by a blinded assessor for two times including motor, function, and feasibility.collected data will be analyzed with nonparametric tests by spss version 20.0, and alpha level was set at .05.

background: spasticity is an important factor limiting independency and activity of daily living for post-stroke patients. splinting has been proved to be successful treatment for spasticity.3d printing technology was used to construct personalized, complicated orthosis, and one piece to reduce assembly time. the evidence most are product development, but few of study investigate the effectiveness. aim: to evaluate the effect of 3d printing functional splints on hand function for patients with stroke. methods: twenty stroke patients with moderate motor deficits were recruited and randomized into experimental (3d printing splint) or control (functional splint) groups for 8 weeks of treatment (sixty minutes for position and twenty minutes for training a time, triple times a day). the performance was assessed by a blinded assessor for two times included fugl-meyer assessment-upper limb section(fma-ue), electromyography (emg), grip dynamometer, passive range of motion (prom) at upper extremity, muscle tone at upper extremity, and disability of the arm, shoulder and hand questionnaire(dash). the splint wearing performance and satisfaction were recorded. collected data will be analyzed with nonparametric tests by spss version 20.0, and alpha level was set at .05.

Eligibility criteria:
inclusion criteria: * cerebral stroke, patients with unilateral hemiplegia * onset is more than three months; * able to understand activity instructions; * fugl-meyer assessment 20-50 points exclusion criteria: * age over 75 years and under 20 years old; * other medical diseases that affect the execution program * modified ashworth scale of wrist and hand greater than 2 points * deformed elbow, wrist and hand joints * treated with botulinum toxin on the upper limbs of the affected side.
assessment of different protocols for cervical dentin hypersensitivity treatment

Conditions: Hypersensitivity Dentin; Dentin Sensitivity; Dentin Hypersensitivity; Dentine Hypersensitivity

Summary: the aim of this study is through a randomized clinical trial, double blind, splith-mouth, evaluate the various types of protocols and clinical efficacy in the reduction or even elimination of dentinal hypersensitivity by the agents desensibilize kf - fgm dental products, clinpro - 3m company, minnesota - usa, photon laser iii - dmc, brazil, desensibilize kf and laser, desensibilize kf and clinpro, laser and clinpro and the association of all products. data will be collected, tabulated and submitted to statistical analysis.

cervical dentin hypersensitivity is a painful condition and is a clinical challenge due to different treatment strategies available. the aim of this study is through a randomized clinical trial, double blind, splith-mouth, evaluate the various types of protocols and clinical efficacy in the reduction or even elimination of dentinal hypersensitivity. a hundred forty teeth of healthy patients of both sexes were selected. visual analog scale was used pain (vas) to measure the intensity of the patient's pain. the teeth will be randomly divided into 7 different groups according to the desensitization treatment under study: desensibilize kf - fgm dental products, clinpro - 3m company, minnesota - usa, photon laser iii - dmc, brazil, desensibilize kf and laser, desensibilize kf and clinpro, laser and clinpro and the association of all products. data will be collected, tabulated and submitted to statistical analysis.

Eligibility criteria:
inclusion criteria: * presence of dentin exposure lesions with clinical diagnosis of moderate or severe tooth sensitivity * good oral hygiene. exclusion criteria: * cavities, * presence of periodontal disease and or parafunctional habits, * cracks or enamel fractures, * extensive or unsatisfactory restorations, * recent restorations involving the labial surface, * dentures, * orthodontics.
review of the paediatric pleuropulmonary blastoma french series

Conditions: Pleuropulmonary Blastoma

Summary: pleuropulmonary blastoma is a rare embryonic malignant tumour that remains the most frequent malignant tumour of the lung in childhood. the international pleuro pulmonary blastoma registry (ippb) found only 220 cases in 2009 and 350 in 2015. in france, 20 cases were identified in 2009. three histologies are described: type 1 purely cystic, type 2 combined and type 3 solid. median age at diagnostic is 12 months, 35 months and 41 months respectively. evolution is possible from type 1 to type 2 or 3 in 10% of the cases. since 2009, dicer 1 mutations research is proposed systematically to all families. ppb symptoms are usually non-specific. diagnostic is evoked when imaging work up shows bubbles or solid lesions, and confirmed by pathological analysis. however the diagnosis can be difficult because of the proximity with congenital cystic adenomatoid malformation. the french society of paediatric oncology recommends surgery at first instance. ppb type 1 remains a problem because some are still misdiagnosed as ccam, a benign lesion. chemotherapy depends on the ppb type and the quality of the resection. there is a real interest to analyse the french series. the prognosis of type 2 and 3 is low with a 5 years survival rate of 45-60%, whereas type 1 survival rate is 91%. the french experience reports a 100% survival rate in type 1 and 48% in type 2 and 3. other prognostic factors are initial size of the tumour, extra pulmonary invasion and quality of surgery. early local relapses are possible and late ones concern more often type 2 and 3 with more cerebral metastasis. in 2009, the french cases were collected, but no update has been performed since. the aim of this retrospective review of the cases since 2000, is to audit the care of ppb patients in france and update the french rare tumour database. evoking ppb diagnosis is difficult when imaging shows a neonatal cystic lesion. there are no radiologic criteria in the literature that differentiate congenital pulmonary cystic lesion and ppb type 1. radiological presentation is however overlapping. another aim of this study will be to look for a predictive sign of type 1 ppb.

multicentre retrospective study

Eligibility criteria:
inclusion criteria: * patients born between 01/01/2000 and 01/01/2016 ; * followed up for ppb * treated in a french department of paediatric oncology or paediatric surgery * study agreement exclusion criteria: * part of the care out of france * study disagreement